Washout kinetics of colloidal starch as a partial or full replacement for plasma exchange

Journal of Clinical Apheresis

Volumn 11, Issue 3, 1996, Pages 123-126

  Brecher, M E ^a,b   Owen, H G ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

apheresis; colloid; exchange; mathematical; modeling; plasma; replacement; starch

Indexed keywords

STARCH;

APHERESIS; ARTICLE; CLINICAL ARTICLE; COLLOID; HUMAN; INFUSION; KINETICS; MATHEMATICAL MODEL; PLASMA VOLUME; PLASMAPHERESIS;

COLLOIDS; COMPUTER SIMULATION; HUMANS; MODELS, THEORETICAL; PLASMA EXCHANGE; STARCH;

EID: 0029845154     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1101(1996)11:3<123::AID-JCA1>3.0.CO;2-D     Document Type: Article

References (15)

1. Vermeulen LC, Ratko TA, Erstad BL, Brecher ME, Matuszewski KA: A Paradigm for consensus: The University Hospital consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Int Med 155:373-379, 1995.
2. Fujii H: Plasma exchange using Dextran 40-electrolyte solution as the sole replacement fluid in malignant paraproteinemia. Transfusion 28:42-45, 1988.
3. Burgstaler EA, Pineda AA: Hydroxyethylstarch as replacement in therapeutic plasma exchange. Prog Clin Biol Res 337:395-397, 1990.
4. Brecher ME, Owen HG, Collins ML: Apheresis and ace inhibitors. Transfusion 33:963-964, 1993.
5. Sutton DMC, Freedman JJL, Nair RC, Rock G: Pentastarch instead of albumin as replacement fluid for therapeutic plasma exchange. (abstract) Transfusion 34:S14, 1994.
6. Owen HG, Brecher ME: Colloid starch replacement solutions for TPE. J Clin Apheresis 11:95 (abstract), 1996.
7. Trivedi SM, Humphrey RL, Braine HG, Frondoza CG: Hydroxyethyl starch serum levels in leukaphersis donors measured by modified periodic acid-Schiff staining technique. Transfusion 24:260-263, 1984.
8. Maguire LC, Strauss RG, Koepke JA, Bowman RJ, Zelenski KR, Lambert RM, Hulse JD, Atnip AK: The elimination of hydroxyethyl starch from the blood of donors experiencing single or multiple intermittent-flow centrifugation leukapheresis. Transfusion 21: 347-353, 1981.
9. Mishler JM, Hester JP, Huestis DW, Rock GA, Strauss RB: Dosage and scheduling regimens for erythrocyte-sedimenting macromolecules. J Chn Apheresis 1:130-143, 1983.
10. Chang JC, Gross HM, Jang NS: Disseminated intravascular coagulation due to intravenous administration of hetastarch. Am J Med Sci 300:301-303, 1990.
11. Parker NE, Porter JB, Williams HJM, Leftley M: Pruritis after administration of hetastarch. BMJ 284:385-386, 1982.
12. Schneeberger R, Albegger K, Oberasheer G, Miller K: Juckreizeine nebenwirkung von hydroxyäthylstärke (HES)? HNO 38:298-303, 1990.
13. Hermann J, Gall H: Diagnose und therapie des persistierenden pruritis nach infusion von hydroxyäthylstärke (HÄS). Aktuel Dermatol 16:166-167, 1990.
14. Jurecka W, Sz'epfalusi Z, Parth E, Schiemetta W, Gebhart W, Scheiner O, Kraft D: Hydroxyethylstarch deposits in human skin - a model for pruritis? Arch Dermatol Res 285:13-19, 1993.
15. Strauss RG: Review of the effects of hydroxyethyl starch on the blood coagulation system. Transfusion 21:299-302, 1981.